General methodological characteristics of the trials
| First author [ref.] | Phase | Primary outcome | Secondary outcomes | IA | Adjustment for IA |
| First-line setting | |||||
| Negoro [13] | III | OS | Response | No | NA |
| Duration of response | |||||
| TTP | |||||
| Toxicity | |||||
| QoL | |||||
| Rosell [14] | III | Response | Toxicity | No | NA |
| QoL | |||||
| OS | |||||
| Fossella [15] | III | OS | Response | Yes | Reported |
| Duration of response | |||||
| TTP | |||||
| Toxicity | |||||
| QoL | |||||
| Ohe [16] | III | 1-year OS | Response | No | NA |
| Duration of response | |||||
| TTF | |||||
| TTP | |||||
| Toxicity | |||||
| QoL | |||||
| Novello [17] | III | OS | Response rate | No | NA |
| 1-year OS | |||||
| Toxicity | |||||
| QoL | |||||
| Park [18] | III | OS | Response | No | NA |
| TTP | |||||
| Toxicity | |||||
| QoL | |||||
| Scagliotti [19] | III | OS | Response | No | NA |
| Duration of response | |||||
| TTF | |||||
| TTP | |||||
| PFS | |||||
| Toxicity | |||||
| Heymach [20] | II | PFS | Response | Yes | Not reported |
| Disease control | |||||
| Toxicity | |||||
| OS | |||||
| Mok [21] | III | PFS | Response | No | NA |
| Reduction in symptoms | |||||
| Toxicity | |||||
| OS | |||||
| QoL | |||||
| Okamoto [22] | III | OS | Response | Yes | Reported |
| PFS | |||||
| Toxicity | |||||
| QoL | |||||
| Lee [23] | IIB | Response | PFS | No | NA |
| Toxicity | |||||
| OS | |||||
| Second-line setting | |||||
| Schuette [24] | III | 1-year OS | Response | No | NA |
| TTP | |||||
| Toxicity | |||||
| QoL | |||||
| Hanna [25] | III | OS | Response | No | NA |
| Duration of CB | |||||
| TTF | |||||
| TTP | |||||
| PFS | |||||
| QoL | |||||
| Ramlau [26] | III | 1-year OS | Response | No | NA |
| Duration of response | |||||
| TTR | |||||
| TTP | |||||
| Toxicity | |||||
| OS | |||||
| QoL | |||||
| Drug exposure | |||||
| Krzakowski [27] | III | PFS | Response | No | NA |
| CB | |||||
| Toxicity | |||||
| OS | |||||
| QoL | |||||
| Maruyama [28] | III | OS | PFS | Yes | Reported |
| Toxicity | |||||
| QoL | |||||
| Kim [29] | III | OS | Response | Yes | Reported |
| PFS | |||||
| Toxicity | |||||
| QoL | |||||
| Li [30] | II# | Response | Disease control | No | NA |
| Performance index scores | |||||
| Toxicity | |||||
| Natale [31] | III | PFS | Response | Yes | Reported |
| Time to symptom deterioration | |||||
| Shi [32] | III | PFS | Response | No | NA |
| TTP | |||||
| Toxicity | |||||
| OS | |||||
| QoL |
IA: interim analysis; OS: overall survival; TTP: time to progression; QoL: quality of life; NA: not applicable; TTF: time to treatment failure; PFS: progression-free survival; CB: clinical benefit; TTR: time to response. #: stated as exploratory.